![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Vol. 300, Issue 2, 549-558, February 2002
-Ethynylestradiol on Activities of Cytochrome
P450 2B (P450 2B) Enzymes: Characterization of Inactivation of P450s
2B1 and 2B6 and Identification of Metabolites
Department of Pharmacology, University of Michigan, Ann Arbor,
Michigan (U.M.K., D.E.M., P.F.H.); and Department of Chemistry, Tulane
University, New Orleans, Louisiana (R.V.R., W.L.A.)
17-
-Ethynylestradiol (17EE) inactivated purified, reconstituted rat
hepatic cytochrome P450 (P450) 2B1 and human P450 2B6 in a
mechanism-based manner. Little or no inactivation was observed when
P450s 2B2 or 2B4 were incubated with 17EE. The inactivation of P450s
2B1 and 2B6 was entirely dependent on both NADPH and 17EE and followed
pseudo-first order kinetics. The maximal rate constants for the
inactivation of P450s 2B1 and 2B6 at 30°C were 0.2 and 0.03 min
1, respectively. For P450s 2B1 and 2B6 the apparent
KI was 11 and 0.8 µM, respectively.
Incubation of P450 2B1 with 17EE and NADPH for 20 min resulted in a
75% loss in enzymatic activity and a concurrent 20 to 25% loss of the
enzyme's ability to form a reduced CO complex. With P450 2B6, an 83%
loss in enzymatic activity and a 5 to 10% loss in the CO reduced
spectrum were observed. The extrapolated partition ratios for 17EE with
P450 2B1 and 2B6 were 21 and 13, respectively. Simultaneous incubation
of an alternate substrate together with 17EE protected both enzymes
from inactivation. A 1.3:1 stoichiometry of labeling for binding of the
radiolabeled 17EE to P450 2B1 and 2B6 was seen. These results indicate
that 17EE inactivates P450s 2B1 and 2B6 in a mechanism-based manner, primarily by the binding of a reactive intermediate of 17EE to the
apoprotein. Analysis of the 17EE metabolites showed that 2B enzymes
that become inactivated differ primarily by their ability to generate
two metabolites that were not produced by P450s 2B2 or 2B4.
This article has been cited by other articles:
|
|
 |
|
  H.-l. Lin, H. Zhang, K. R. Noon, and P. F. Hollenberg Mechanism-Based Inactivation of CYP2B1 and Its F-Helix Mutant by Two tert-Butyl Acetylenic Compounds: Covalent Modification of Prosthetic Heme Versus Apoprotein J. Pharmacol. Exp. Ther., November 1, 2009; 331(2): 392 - 403. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Zhang, C. Kenaan, D. Hamdane, G. H. B. Hoa, and P. F. Hollenberg Effect of Conformational Dynamics on Substrate Recognition and Specificity as Probed by the Introduction of a de Novo Disulfide Bond into Cytochrome P450 2B1 J. Biol. Chem., September 18, 2009; 284(38): 25678 - 25686. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-Y. Chang, C. Chen, Z. Yang, and A. D. Rodrigues Further Assessment of 17{alpha}-Ethinyl Estradiol as an Inhibitor of Different Human Cytochrome P450 Forms in Vitro Drug Metab. Dispos., August 1, 2009; 37(8): 1667 - 1675. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-l. Lin, H. Zhang, and P. F. Hollenberg Metabolic Activation of Mifepristone [RU486; 17{beta}-Hydroxy-11{beta}-(4-dimethylaminophenyl)-17{alpha}-(1-propynyl)-estra-4,9-dien-3-one] by Mammalian Cytochromes P450 and the Mechanism-Based Inactivation of Human CYP2B6 J. Pharmacol. Exp. Ther., April 1, 2009; 329(1): 26 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. N. Bumpus and P. F. Hollenberg Investigation of the Mechanisms Underlying the Differential Effects of the K262R Mutation of P450 2B6 on Catalytic Activity Mol. Pharmacol., October 1, 2008; 74(4): 990 - 999. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. N. Bumpus, U. M. Kent, and P. F. Hollenberg Metabolism of Efavirenz and 8-Hydroxyefavirenz by P450 2B6 Leads to Inactivation by Two Distinct Mechanisms J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 345 - 351. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Hesse, D. J. Greenblatt, L. L. von Moltke, and M. H. Court Ritonavir has minimal impact on the pharmacokinetic disposition of a single dose of bupropion administered to human volunteers. J. Clin. Pharmacol., May 1, 2006; 46(5): 567 - 576. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. N. Bumpus, C. Sridar, U. M. Kent, and P. F. Hollenberg THE NATURALLY OCCURRING CYTOCHROME P450 (P450) 2B6 K262R MUTANT OF P450 2B6 EXHIBITS ALTERATIONS IN SUBSTRATE METABOLISM AND INACTIVATION Drug Metab. Dispos., June 1, 2005; 33(6): 795 - 802. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-L. Lin, U. M. Kent, H. Zhang, L. Waskell, and P. F. Hollenberg The Functional Role of Threonine-205 in the Mechanism-Based Inactivation of P450 2B1 by Two Ethynyl Substrates: The Importance of the F Helix in Catalysis J. Pharmacol. Exp. Ther., December 1, 2004; 311(3): 855 - 863. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. B. Von Weymarn, C. Sridar, and P. F. Hollenberg Identification of Amino Acid Residues Involved in the Inactivation of Cytochrome P450 2B1 by Two Acetylenic Compounds: The Role of Three Residues in Nonsubstrate Recognition Sites J. Pharmacol. Exp. Ther., October 1, 2004; 311(1): 71 - 79. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Lang, K. Klein, T. Richter, A. Zibat, R. Kerb, M. Eichelbaum, M. Schwab, and U. M. Zanger Multiple Novel Nonsynonymous CYP2B6 Gene Polymorphisms in Caucasians: Demonstration of Phenotypic Null Alleles J. Pharmacol. Exp. Ther., October 1, 2004; 311(1): 34 - 43. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Harleton, M. Webster, N. N. Bumpus, U. M. Kent, J. M. Rae, and P. F. Hollenberg Metabolism of N,N',N''-Triethylenethiophosphoramide by CYP2B1 and CYP2B6 Results in the Inactivation of Both Isoforms by Two Distinct Mechanisms J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 1011 - 1019. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Desaulniers, K. Leingartner, B. Musicki, A. Yagminas, G.-H. Xiao, J. Cole, L. Marro, M. Charbonneau, and B. K. Tsang Effects of Postnatal Exposure to Mixtures of Non-ortho-PCBs, PCDDs, and PCDFs in Prepubertal Female Rats Toxicol. Sci., October 1, 2003; 75(2): 468 - 480. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-L. Lin, H. Zhang, L. Waskell, and P. F. Hollenberg Threonine-205 in the F Helix of P450 2B1 Contributes to Androgen 16{beta}-Hydroxylation Activity and Mechanism-Based Inactivation J. Pharmacol. Exp. Ther., August 1, 2003; 306(2): 744 - 751. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. W. Fan, C. Gu, S. A. Marsh, and J. C. Stevens Mechanism-Based Inactivation of Cytochrome P450 2B6 by a Novel Terminal Acetylene Inhibitor Drug Metab. Dispos., January 1, 2003; 31(1): 28 - 36. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-l. Lin, U. M. Kent, and P. F. Hollenberg Mechanism-Based Inactivation of Cytochrome P450 3A4 by 17alpha -Ethynylestradiol: Evidence for Heme Destruction and Covalent Binding to Protein J. Pharmacol. Exp. Ther., April 1, 2002; 301(1): 160 - 167. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
